A Multicenter Randomized Phase II Study of Docetaxel vs. Docetaxel Plus Cisplatin vs. Docetaxel Plus S-1 as Second-Line Chemotherapy in Metastatic Gastric Cancer Patients Who Had Progressed after Cisplatin Plus Either S-1 or Capecitabine
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose This study evaluated the re-challenge of S-1 or cisplatin in combination with docetaxel in metastatic gastric cancer (MGC) that had progressed on a cisplatin plus either S-1 or capecitabine regimen. Materials and Methods Patients with progressive disease after first-line cisplatin plus S-1 or capecitabine were randomized to receive 3-week cycles of docetaxel 75 mg/m2 intravenously (IV) on D1 (D), docetaxel 60 mg/m2 IV plus cisplatin 60 mg/m" IV on D1 (DC), or docetaxel 60 mg/m2 IV D1 plus oral S-1 30 mg/m2 twice a day on D1-14 (DS). Results Seventy-two patients were randomized to the D (n=23), DC (n=24), or DS (n=25) group. The confirmed response rate was 4.3% (95% confidence interval [CI], 0% to 12.6%), 4.3% (95% CI, 0% to 12.6%), and 8.7% (95% CI, 0% to 20.2%) for the D, DC, and DS groups, respectively. Compared to the D arm, the DS arm had a better progression-free survival (2.7 months vs. 1.3 months, p=0.034) without any deterioration in safety or quality of life, whereas the DC arm had a similar progression-free survival (1.8 months vs. 1.3 months, p=0.804) and poorer overall survival (5.6 months vs. 10.0 months, p=0.035). Conclusion A re-challenge with S-1, but not cisplatin, in combination with docetaxel has potential anticancer benefits over docetaxel alone in MGC with progression after prior cisplatin plus S-1 or capecitabine.
Abstract
Purpose This study evaluated the re-challenge of S-1 or cisplatin in combination with docetaxel in metastatic gastric cancer (MGC) that had progressed on a cisplatin plus either S-1 or capecitabine regimen. Materials and Methods Patients with progressive disease after first-line cisplatin plus S-1 or capecitabine were randomized to receive 3-week cycles of docetaxel 75 mg/m2 intravenously (IV) on D1 (D), docetaxel 60 mg/m2 IV plus cisplatin 60 mg/m" IV on D1 (DC), or docetaxel 60 mg/m2 IV D1 plus oral S-1 30 mg/m2 twice a day on D1-14 (DS). Results Seventy-two patients were randomized to the D (n=23), DC (n=24), or DS (n=25) group. The confirmed response rate was 4.3% (95% confidence interval [CI], 0% to 12.6%), 4.3% (95% CI, 0% to 12.6%), and 8.7% (95% CI, 0% to 20.2%) for the D, DC, and DS groups, respectively. Compared to the D arm, the DS arm had a better progression-free survival (2.7 months vs. 1.3 months, p=0.034) without any deterioration in safety or quality of life, whereas the DC arm had a similar progression-free survival (1.8 months vs. 1.3 months, p=0.804) and poorer overall survival (5.6 months vs. 10.0 months, p=0.035). Conclusion A re-challenge with S-1, but not cisplatin, in combination with docetaxel has potential anticancer benefits over docetaxel alone in MGC with progression after prior cisplatin plus S-1 or capecitabine.
참고문헌 (30)
- 정규원, "Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2012", Cancer Research and Treatment, 47(2), pp.127~141 (2015), 대한암학회[DOI]
- Glimelius B, "Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer", Ann Oncol, 8, pp.163~168 (1997)
- Kang YK, "Capecitabine", cisplatin versus 5-fluorouracil, Ann Oncol, pp.2009, 20[DOI]
- Cunningham D, "Capecitabine and oxaliplatin for advanced esophagogastric cancer", N Engl J Med, 358, pp.36~46 (2008)
- Ajani JA, "Multicenter phase III comparison of cisplatin", S-1 with cisplatin, J Clin Oncol, pp.2010, 28[DOI]
- Koizumi W, "S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer(SPIRITS trial) : a phase III trial", Lancet Oncol, 9, pp.215~221 (2008)
- Boku N, "Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer : a randomised phase 3 study", Lancet Oncol, 10, pp.1063~1069 (2009)
- Thuss-Patience PC, "Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer : a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie(AIO)", Eur J Cancer, 47, pp.2306~2314 (2011)
- Ford HE, "Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma(COUGAR-02) : an open-label, phase 3 randomised controlled trial", Lancet Oncol, 15, pp.78~86 (2014)
- Kang JH, "Salvage chemotherapy for pretreated gastric cancer : a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone", J Clin Oncol, 30, pp.1513~1518 (2012)
- Takahashi I, "Increased antitumor activity in combined treatment TS-1 and docetaxel : a preclinical study using gastric cancer xenografts", Oncology, 68, pp.130~137 (2005)
- Wada Y, "Synergistic effects of docetaxel and S-1 by modulating the expression of metabolic enzymes of 5-fluorouracil in human gastric cancer cell lines", Int J Cancer, 119, pp.783~791 (2006)
- Maeda S, "Docetaxel enhances the cytotoxicity of cisplatin to gastric cancer cells by modification of intracellular platinum metabolism", Cancer Sci, 95, pp.679~684 (2004)
- Takiuchi H, "Thymidylate synthase gene expression in primary tumors predicts activity of s-1-based chemotherapy for advanced gastric cancer", Gastrointest Cancer Res, 1, pp.171~176 (2007)
- Endo K, "Expression of multidrug-resistance-associated protein(MRP)and chemosensitivity in human gastric cancer", Int J Cancer, 68, pp.372~377 (1996)
- Lee JL, "A phase II study of docetaxel as salvage chemotherapy in advanced gastric cancer after failure of fluoropyrimidine and platinum combination chemotherapy", Cancer Chemother Pharmacol, 61, pp.631~637 (2008)
- Kunisaki C, "Phase II study of docetaxel plus cisplatin as a second-line combined therapy in patients with advanced gastric carcinoma", Anticancer Res, 25, pp.2973~2977 (2005)
- Polyzos A, "Subsets of patients with advanced gastric cancer responding to second-line chemotherapy with docetaxel-cisplatin", Anticancer Res, 26, pp.3749~3753 (2006)
- Park SH, "Docetaxel plus cisplatin as second-line therapy in metastatic or recurrent advanced gastric cancer progressing on 5-fluorouracil-based regimen", Am J Clin Oncol, 27, pp.477~480 (2004)
- Kim H, "A phase II study of docetaxel and cisplatin in patients with gastric cancer recurring after or progressing during 5-FU", platinum treatment, 2005, pp.35, 727~732
- Yoshida K, "Phase II study of docetaxel and S-1combination therapy for advanced or recurrent gastric cancer", Clin Cancer Res, 12(11 Pt 1), pp.3402~3407 (2006)
- Koizumi W, "Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer : a randomized study(START)", J Cancer Res Clin Oncol, 140, pp.319~328 (2014)
- Therasse P, "New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada", J Natl Cancer Inst, 92, pp.205~216 (2000)
- Hironaka S, "Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum : WJOG 4007 trial", J Clin Oncol, 31, pp.4438~4444 (2013)
- Higuchi K, "Biweekly irinotecan plus cisplatin versus irinotecan alone as second-line treatment for advanced gastric cancer : a randomised phase III trial(TCOG GI-0801", BIRIP trial), 2014, pp.50, 1437~1445
- Nishikawa K, "Randomised phase III trial of second-line irinotecan plus cisplatin versus irinotecan alone in patients with advanced gastric cancer refractory to S-1 monotherapy : TRICS trial", Eur J Cancer, 51, pp.808~816 (2015)
- Tanabe K, "Phase II", III study of second-line chemotherapy comparing irinotecan-alone with S-1 plus irinotecan in advanced gastric cancer refractory to first-line treatment with S-1(JACCRO GC-05), 2015, pp.26, 1916~1922
- Rothenberg ML, "Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin : interim results of a phase III trial", J Clin Oncol, 21, pp.2059~2069 (2003)
- Seymour MT, "Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer(MRC FOCUS) : a randomised controlled trial", Lancet, 370, pp.143~152 (2007)
- Tournigand C, "FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer : a randomized GERCOR study", J Clin Oncol, 22, pp.229~237 (2004)